biOasis Technologies Inc. announced thatRob Hutchison, biOasis founder, former chief executive officer and current chairman of the board of directors (BoD), will retire as chairman and board member, effective Dec. 31, 2017. Board member Michael Hutchison will also step down from the biOasis BoD in October 2017. The Company recently announced the nominations of three exemplary, world-class biotech and pharmaceutical executives to the board of directors. Dr. Maha Radhakrishnan, Dr. Deborah Rathjen and Dr. Nancy Stagliano are formidable executives and are 100% committed to actively working to help shape the company. Chief Scientist Dr. Reinhard Gabathuler is no longer with the Company. Dr. Day will serve as chief scientist, effective immediately, with support from the newly formed scientific advisory board (SAB) and Dr. Mei Mei Tian; Dr. Tian has been promoted to vice president of external research; Warren K. Volles, Esq. from IPraxus Legal, LLC has been retained to lead the Company’s intellectual property strategy as well as to maintain and expand the Company’s current IP portfolio, among other responsibilities.